Shattuck Labs Inc - Asset Resilience Ratio
Shattuck Labs Inc (STTK) has an Asset Resilience Ratio of 43.44% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Shattuck Labs Inc's Asset Resilience Ratio has changed over time. Check Shattuck Labs Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Shattuck Labs Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see STTK market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $43.58 Million | 43.44% |
| Total Liquid Assets | $43.58 Million | 43.44% |
Asset Resilience Insights
- Very High Liquidity: Shattuck Labs Inc maintains exceptional liquid asset reserves at 43.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Shattuck Labs Inc Industry Peers by Asset Resilience Ratio
Compare Shattuck Labs Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Shattuck Labs Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Shattuck Labs Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.13% | $15.60 Million | $91.05 Million | +14.00pp |
| 2023-12-31 | 3.13% | $5.00 Million | $159.56 Million | -52.34pp |
| 2022-12-31 | 55.47% | $113.90 Million | $205.32 Million | -3.65pp |
| 2021-12-31 | 59.12% | $176.54 Million | $298.58 Million | +8.25pp |
| 2020-12-31 | 50.88% | $177.55 Million | $348.99 Million | -20.45pp |
| 2019-12-31 | 71.32% | $32.07 Million | $44.97 Million | +29.17pp |
| 2018-12-31 | 42.15% | $28.73 Million | $68.16 Million | -- |
About Shattuck Labs Inc
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inf… Read more